Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Gross Margin (2016 - 2026)

Ocular Therapeutix has reported Gross Margin over the past 13 years, most recently at 87.68% for Q1 2026.

  • For Q1 2026, Gross Margin rose 11993.0% year-over-year to 87.68%; the TTM value through Mar 2026 reached 65.4%, up 1144.0%, while the annual FY2025 figure was 3.79%, 9497.0% down from the prior year.
  • Gross Margin for Q1 2026 was 87.68% at Ocular Therapeutix, up from 2.21% in the prior quarter.
  • Over five years, Gross Margin peaked at 92.81% in Q4 2022 and troughed at 147.65% in Q4 2023.
  • A 5-year average of 45.57% and a median of 85.56% in 2025 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: crashed -24046bps in 2023 and later soared 24044bps in 2024.
  • Year by year, Gross Margin stood at 92.81% in 2022, then tumbled by -259bps to 147.65% in 2023, then soared by 163bps to 92.8% in 2024, then plummeted by -98bps to 2.21% in 2025, then surged by 3865bps to 87.68% in 2026.
  • Business Quant data shows Gross Margin for OCUL at 87.68% in Q1 2026, 2.21% in Q4 2025, and 87.8% in Q3 2025.